# China NMPA Drug Inspection - Beijing Tongrentang (Bozhou) Pharmaceutical Co., Ltd. - alum

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/beijing-tongrentang-bozhou-pharmaceutical-co-ltd/8ceb21e6-a470-476c-9f59-e8fb6a561d73/
Source feed: China

> China NMPA drug inspection for Beijing Tongrentang (Bozhou) Pharmaceutical Co., Ltd. published July 20, 2017. Drug: alum. The State Administration for Market Regulation (now NMPA) issued Announcement No. 113 of 2017 on July 20, 2017, concerni

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 113 of 2017 from the State Administration of Traditional Chinese Medicine regarding 26 batches of substandard prepared slices of traditional Chinese medicine.
- Company Name: Beijing Tongrentang (Bozhou) Pharmaceutical Co., Ltd.
- Publication Date: 2017-07-20
- Drug Name: alum
- Inspection Finding: The alum failed the test; the unqualified item was ammonium salts.
- Action Taken: Seize and detain products, suspend sales and use, recall products and rectify the issues; initiate investigations into illegal activities involving the production and sale of substandard drugs.
- Summary: The State Administration for Market Regulation (now NMPA) issued Announcement No. 113 of 2017 on July 20, 2017, concerning 26 batches of unqualified Traditional Chinese Medicine (TCM) decoction pieces. Investigations conducted by the China National Institutes for Food and Drug Control identified products from 20 companies, including Anhui Hukun Traditional Chinese Medicine Decoction Pieces Co., Ltd. and Beijing Meikangtang Pharmaceutical Technology Co., Ltd., as substandard. The core violation was the detection of ammonium salts in alum. Provincial food and drug administrations took immediate control measures, such as sealing and seizing affected products, and mandated companies to suspend sales, recall non-compliant batches, and rectify issues. The State Food and Drug Administration, operating under Articles 73, 74, and 75 of the Drug Administration Law of the People's Republic of China, required provincial authorities to investigate these illegal acts and publicize the handling results within three months. Companies disputing product authenticity face rigorous investigation, with severe penalties for confirmed manufacturers of substandard drugs.

Company: https://www.globalkeysolutions.net/companies/beijing-tongrentang-bozhou-pharmaceutical-co-ltd/7216e765-9728-4313-a8dd-7ea1d6ac6377/